BHB810 for adenocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Apr 2026: Trial registered, NCT07529808
  2. 16 Jul 2026: Trial started, NCT07529808

The trials

NCT07529808: Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

State
Under way
Phase
Phase 1 and Phase 2
People
164 planned
Started
16 Jul 2026
Primary completion
Dec 2028
Arms
Dose Escalation and Backfill Cohorts, Recommended Phase 2 Dose Level 1 (RP2D1), Recommended Phase 2 Dose Level 2 (RP2D2)
Results
None posted
  1. 14 Apr 2026: Trial registered
  2. 16 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.